Maplight Therapeutics (NASDAQ:MPLT) Insider Jonathan Gillis Sells 51,900 Shares

Maplight Therapeutics, Inc. (NASDAQ:MPLT) insider Jonathan Gillis sold 51,900 shares of the stock in a transaction that occurred on Monday, April 27th. The shares were sold at an average price of $29.74, for a total value of $1,543,506.00. Following the transaction, the insider directly owned 199,154 shares of the company’s stock, valued at $5,922,839.96. The trade was a 20.67% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Jonathan Gillis also recently made the following trade(s):

• On Tuesday, April 28th, Jonathan Gillis sold 17,935 shares of Maplight Therapeutics stock. The stock was sold at an average price of $30.35, for a total value of $544,327.25.

Maplight Therapeutics Price Performance

Shares of MPLT opened at $30.29 on Thursday. The stock’s 50 day moving average price is $21.91. Maplight Therapeutics, Inc. has a one year low of $12.24 and a one year high of $33.28. The stock has a market capitalization of $1.29 billion and a PE ratio of -0.76.

Maplight Therapeutics (NASDAQ:MPLT) last announced its quarterly earnings data on Thursday, March 26th. The company reported ($2.47) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.05) by ($1.42). Sell-side analysts predict that Maplight Therapeutics, Inc. will post -3.87 EPS for the current year.

Hedge Funds Weigh In On Maplight Therapeutics

A number of hedge funds have recently made changes to their positions in the stock. Strs Ohio acquired a new stake in Maplight Therapeutics in the 4th quarter valued at approximately $53,000. Police & Firemen s Retirement System of New Jersey purchased a new position in shares of Maplight Therapeutics during the fourth quarter worth $70,000. New York State Common Retirement Fund acquired a new stake in shares of Maplight Therapeutics in the fourth quarter valued at $93,000. MetLife Investment Management LLC acquired a new stake in shares of Maplight Therapeutics in the fourth quarter valued at $172,000. Finally, Walleye Capital LLC purchased a new stake in shares of Maplight Therapeutics in the 4th quarter valued at $205,000.

Analysts Set New Price Targets

A number of equities analysts recently weighed in on MPLT shares. TD Cowen initiated coverage on shares of Maplight Therapeutics in a research report on Tuesday, April 7th. They set a “buy” rating on the stock. Wall Street Zen downgraded shares of Maplight Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, March 21st. Needham & Company LLC assumed coverage on Maplight Therapeutics in a report on Wednesday, April 8th. They set a “buy” rating and a $37.00 target price on the stock. Canaccord Genuity Group started coverage on Maplight Therapeutics in a research report on Thursday, March 19th. They issued a “buy” rating and a $35.00 price target for the company. Finally, Weiss Ratings assumed coverage on Maplight Therapeutics in a report on Thursday, January 22nd. They issued a “sell (e)” rating for the company. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $32.67.

About Maplight Therapeutics

We are a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system, or CNS, disorders. We were founded by globally recognized leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies available for patients. Our discovery platform holds the potential to fill this void by identifying neural circuits causally linked to disease and targeting those circuits for therapeutic modulation.